Analyst Ratings For Galmed Pharmaceuticals (NASDAQ:GLMD)
Today, Maxim Group reiterated its Buy rating on Galmed Pharmaceuticals (NASDAQ:GLMD) with a price target of $14.00.
There are 3 buy ratings on the stock.
The current consensus rating on Galmed Pharmaceuticals (NASDAQ:GLMD) is Buy (Score: 3.00) with a consensus target price of $15.33 per share, a potential 117.49% upside.
Some recent analyst ratings include
- 7/31/2017-Maxim Group Reiterated Rating of Buy .
- 7/6/2016-Roth Capital Reiterated Rating of Buy.
- 8/19/2015-MLV & Co. Reiterated Rating of Buy.
Recent Trading Activity for Galmed Pharmaceuticals (NASDAQ:GLMD)
Shares of Galmed Pharmaceuticals closed the previous trading session at 7.05 down -0.74 -9.50% with 41,298 shares trading hands.